Trending Stock News

Marinus Pharmaceuticals, Inc. (MRNS) Reaches $6.58 After 5.00% Up Move; The Habit Restaurants, Inc. (HABT) Covered By 6 Bulls

The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is a huge mover today! The stock increased 1.31% or $0.085 during the last trading session, reaching $6.575. About 476,092 shares traded. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has declined 74.89% since January 17, 2017 and is downtrending. It has underperformed by 91.59% the S&P500.The move comes after 7 months positive chart setup for the $265.83M company. It was reported on Jan, 17 by Barchart.com. We have $6.90 PT which if reached, will make NASDAQ:MRNS worth $13.29 million more.

Among 10 analysts covering The Habit Restaurants Inc (NASDAQ:HABT), 6 have Buy rating, 0 Sell and 4 Hold. Therefore 60% are positive. The Habit Restaurants Inc had 20 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of The Habit Restaurants, Inc. (NASDAQ:HABT) has “Buy” rating given on Tuesday, December 1 by Guggenheim. Stephens maintained the stock with “Overweight” rating in Wednesday, October 11 report. The rating was maintained by Wedbush on Thursday, August 3 with “Buy”. The firm has “Outperform” rating given on Wednesday, March 2 by Cowen & Co. The firm has “Neutral” rating by Wedbush given on Tuesday, September 26. The firm has “Outperform” rating by Raymond James given on Wednesday, August 19. Tigress Financial upgraded The Habit Restaurants, Inc. (NASDAQ:HABT) on Tuesday, November 17 to “Buy” rating. As per Monday, September 11, the company rating was maintained by Cowen & Co. The firm has “Market Perform” rating by Raymond James given on Thursday, November 2. The rating was downgraded by Robert W. Baird on Thursday, November 2 to “Hold”. See The Habit Restaurants, Inc. (NASDAQ:HABT) latest ratings:

13/12/2017 Broker: Maxim Group Rating: Buy New Target: $13.0
02/11/2017 Broker: Robert W. Baird Rating: Hold New Target: $12.0 Downgrade
02/11/2017 Broker: Raymond James Old Rating: Outperform New Rating: Market Perform Downgrade
11/10/2017 Broker: Stephens Rating: Overweight Old Target: $21 New Target: $18 Maintain
09/10/2017 Broker: Robert W. Baird Rating: Buy New Target: $20.0 Maintain
26/09/2017 Broker: Wedbush Old Rating: Outperform New Rating: Neutral Downgrade
11/09/2017 Broker: Cowen & Co Rating: Hold New Target: $16.0 Maintain
03/08/2017 Broker: Piper Jaffray Rating: Buy New Target: $17.0000 Maintain
03/08/2017 Broker: Wedbush Rating: Buy Maintain
03/08/2017 Broker: Cowen & Co Old Rating: Outperform New Rating: Market Perform Downgrade

Investors sentiment increased to 2.8 in 2017 Q3. Its up 2.26, from 0.54 in 2017Q2. It is positive, as 8 investors sold Marinus Pharmaceuticals, Inc. shares while 2 reduced holdings. 20 funds opened positions while 8 raised stakes. 18.97 million shares or 171.42% more from 6.99 million shares in 2017Q2 were reported. J Goldman And Company Lp has 54,000 shares. Jennison Assoc accumulated 1.61M shares. Orbimed Ltd Liability Corporation invested in 0.03% or 567,600 shares. Deerfield Mngmt Company reported 1.36M shares. Adage Capital Partners Gp Limited Com, a Massachusetts-based fund reported 600,000 shares. Susquehanna Int Group Inc Llp invested in 85,618 shares or 0% of the stock. Morgan Stanley reported 280 shares stake. Iguana Health Mngmt Limited Liability Corporation reported 0.57% stake. Franklin Res has invested 0.01% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Bogle Management Lp De owns 382,619 shares or 0.15% of their US portfolio. State Street has invested 0% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Northern Tru Corp invested 0% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Ecor1 Capital Lc reported 3.62 million shares or 2.83% of all its holdings. Granite Point Cap Lp has 2.68 million shares. Caxton has invested 0.1% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS).

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company has market cap of $265.83 million. The firm is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. It currently has negative earnings. The firm is also developing ganaxolone IV formulation to treat status epilepticus.

Among 4 analysts covering Marinus Pharmaceuticals (NASDAQ:MRNS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Marinus Pharmaceuticals had 9 analyst reports since August 5, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Tuesday, June 14. Oppenheimer maintained the shares of MRNS in report on Wednesday, August 5 with “Outperform” rating. Oppenheimer maintained the stock with “Outperform” rating in Friday, October 30 report. As per Tuesday, June 14, the company rating was downgraded by RBC Capital Markets. Jefferies initiated Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) on Tuesday, November 17 with “Buy” rating. Jefferies maintained Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) rating on Wednesday, August 10. Jefferies has “Buy” rating and $3 target. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, March 8. The firm has “Outperform” rating given on Thursday, December 17 by RBC Capital Markets. Oppenheimer downgraded the shares of MRNS in report on Tuesday, June 14 to “Perform” rating.

Since December 15, 2017, it had 0 buys, and 1 insider sale for $10.02 million activity. 1.27 million shares were sold by Bain Capital Life Sciences Investors – LLC, worth $10.02M.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *